Namodenoson

Drug Profile

Namodenoson

Alternative Names: CF-102; Cl-IB-MECA

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Can-Fite BioPharma; Rabin Medical Center; Temple University School of Medicine
  • Class Amides; Anti-inflammatories; Antineoplastics; Antivirals; Iodobenzenes; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • Preclinical Colorectal cancer; Malignant melanoma; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Prostate cancer; Reperfusion injury
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 09 Jan 2017 Can-Fite receives Institutional Review Boards (IRB) approval to commence patient enrolment in phase II trial for NAFLD/NASH in Q1 2017
  • 25 Oct 2016 CF 102 licensed to Chong Kun Dang Pharmaceuticals in South Korea
  • 25 Oct 2016 Can-Fite BioPharma plans a phase III trial for Hepatocellular carcinoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top